Yuval Mika - May 8, 2024 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
General Manager and Chief Technology Officer, Bioelectronic Therapies
Signature
/s/ Matthew R. Schob, Attorney-in-Fact
Stock symbol
OBIO
Transactions as of
May 8, 2024
Transactions value $
$0
Form type
4
Date filed
5/10/2024, 05:25 PM
Previous filing
Jul 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OBIO Common Stock, par value $0.0001 per share ("Common Stock") Award $0 +69.3K +77.4% $0.00 159K May 8, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 10,400 RSUs will vest on May 18, 2025, and (ii) the remaining 58,933 RSUs will vest in equal installments on August 18, 2025, November 18, 2025, December 18, 2025, May 18, 2026, August 18, 2026, November 18, 2026, March 25, 2027, May 18, 2027, August 18, 2027, November 18, 2027, March 25, 2028 and May 18, 2028, subject to the Reporting Person's continuous service through such dates.

Remarks:

General Manager and Chief Technology Officer, Bioelectronic Therapies